HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antifungal activity of maytenin and pristimerin.

Abstract
Fungal infections in humans have increased alarmingly in recent years, particularly in immunocompromised individuals. Among the infections systemic candidiasis, aspergillosis, cryptococcosis, paracoccidioidomycosis, and histoplasmosis mortality are more prevalent and more severe in humans. The current high incidence of dermatophytosis is in humans, especially as the main etiologic agents Trichophyton rubrum and Trichophyton mentagrophytes. Molecules pristimerin and maytenin obtained from the plant Maytenus ilicifolia (Celastraceae) are known to show various pharmacological activities. This study aimed to evaluate the spectrum of antifungal activity of maytenin and pristimerin and their cytotoxicity in human keratinocytes (NOK cells of the oral mucosa). It was concluded that the best spectrum of antifungal activity has been shown to maytenin with MIC varying from 0.12 to 125 mg/L, although it is also active with pristimerin MIC ranging between 0.12 and 250 mg/L. Regarding the toxicity, both showed to have high IC(50). The SI showed high pristimerin against some species of fungi, but SI maytenin was above 1.0 for all fungi tested, showing a selective action of fungi. However, when comparing the two substances, maytenin also showed better results. The two molecules can be a possible prototype with a broad spectrum of action for the development of new antifungal agents.
AuthorsFernanda P Gullo, Janaina C O Sardi, Vânia A F F M Santos, Fernanda Sangalli-Leite, Nayla S Pitangui, Suélen A Rossi, Ana C A de Paula E Silva, Luciana A Soares, Julhiany F Silva, Haroldo C Oliveira, Maysa Furlan, Dulce H S Silva, Vanderlan S Bolzani, Maria José S Mendes-Giannini, Ana Marisa Fusco-Almeida
JournalEvidence-based complementary and alternative medicine : eCAM (Evid Based Complement Alternat Med) Vol. 2012 Pg. 340787 ( 2012) ISSN: 1741-4288 [Electronic] United States
PMID22675379 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: